Concretely: survodutide · 12.5 mg.
Please show the division. I want to check my own against yours.
I would like the general form as well as the specific number, so I can apply it again.
Is my approach right even if my number is wrong?
12.5 mg a week is 650 mg a year and 54.2 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 650 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.
The relevant arithmetic is that a fifteen per cent price advantage disappears against a ten per cent content shortfall plus a testing cost.
Cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.
Put another way, carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.
Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.
Decide whether you are optimising cost or confidence before you build the model.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe underlying point is that this is a spreadsheet question and doing it properly changes conclusions more often than people expect.
Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.
Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.
Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.
Larger orders are cheaper per milligram and concentrate lot risk. Price both.
Answering this needs the order size, because carriage and testing amortise very differently across one vial and across ten.
Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.
Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.
A spreadsheet built on label claim rather than measured content is precise about the wrong number.
Divide by measured content, not by label claim. That is the whole correction.
Put another way, wastage from expired reconstituted vials is a real line item and nobody includes it.
The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.
Independent testing prices at the services this community uses are published and are stable enough to model.
Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.
Fixed-needle syringes save more peptide than most price differences do.
edited 10 Feb 2026 by dead_volume — clarified the distinction between purity and content
Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.
Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Include carriage and testing as per-milligram terms. They dominate small orders.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.